Literature DB >> 34793867

Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning.

Krishnakant Saboo1, Nikita V Petrakov1, Amirhossein Shamsaddini2, Andrew Fagan3, Edith A Gavis3, Masoumeh Sikaroodi2, Sara McGeorge3, Patrick M Gillevet2, Ravishankar K Iyer1, Jasmohan S Bajaj4.   

Abstract

BACKGROUND & AIMS: Saliva and stool microbiota are altered in cirrhosis. Since stool is logistically difficult to collect compared to saliva, it is important to determine their relative diagnostic and prognostic capabilities. We aimed to determine the ability of stool vs. saliva microbiota to differentiate between groups based on disease severity using machine learning (ML).
METHODS: Controls and outpatients with cirrhosis underwent saliva and stool microbiome analysis. Controls vs. cirrhosis and within cirrhosis (based on hepatic encephalopathy [HE], proton pump inhibitor [PPI] and rifaximin use) were classified using 4 ML techniques (random forest [RF], support vector machine, logistic regression, and gradient boosting) with AUC comparisons for stool, saliva or both sample types. Individual microbial contributions were computed using feature importance of RF and Shapley additive explanations. Finally, thresholds for including microbiota were varied between 2.5% and 10%, and core microbiome (DESeq2) analysis was performed.
RESULTS: Two hundred and sixty-nine participants, including 87 controls and 182 patients with cirrhosis, of whom 57 had HE, 78 were on PPIs and 29 on rifaximin were included. Regardless of the ML model, stool microbiota had a significantly higher AUC in differentiating groups vs. saliva. Regarding individual microbiota: autochthonous taxa drove the difference between controls vs. patients with cirrhosis, oral-origin microbiota the difference between PPI users/non-users, and pathobionts and autochthonous taxa the difference between rifaximin users/non-users and patients with/without HE. These were consistent with the core microbiome analysis results.
CONCLUSIONS: On ML analysis, stool microbiota composition is significantly more informative in differentiating between controls and patients with cirrhosis, and those with varying cirrhosis severity, compared to saliva. Despite logistic challenges, stool should be preferred over saliva for microbiome analysis. LAY
SUMMARY: Since it is harder to collect stool than saliva, we wanted to test whether microbes from saliva were better than stool in differentiating between healthy people and those with cirrhosis and, among those with cirrhosis, those with more severe disease. Using machine learning, we found that microbes in stool were more accurate than saliva alone or in combination, therefore, stool should be preferred for analysis and collection wherever possible.
Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Machine Learning; Proton pump inhibitors; Random Forest classifier; Rifaximin; SHAP

Mesh:

Year:  2021        PMID: 34793867      PMCID: PMC8858861          DOI: 10.1016/j.jhep.2021.11.011

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  25 in total

1.  Is treating the gut microbiome the key to achieving better outcomes in cirrhosis?

Authors:  Grace Hatton; Debbie L Shawcross
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2018-11-13       Impact factor: 3.869

2.  Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.

Authors:  Jasmohan S Bajaj; Phillip B Hylemon; Jason M Ridlon; Douglas M Heuman; Kalyani Daita; Melanie B White; Pamela Monteith; Nicole A Noble; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-07-19       Impact factor: 4.052

3.  Alterations in Skin Microbiomes of Patients With Cirrhosis.

Authors:  Jasmohan S Bajaj; Andrew Fagan; Masoumeh Sikaroodi; Genta Kakiyama; Hajme Takei; Yordanos Degefu; William M Pandak; Phillip B Hylemon; Michael Fuchs; Binu John; Douglas M Heuman; Edith Gavis; Hiroshi Nittono; Rohan Patil; Patrick M Gillevet
Journal:  Clin Gastroenterol Hepatol       Date:  2019-03-21       Impact factor: 11.382

4.  Alterations of the human gut microbiome in liver cirrhosis.

Authors:  Nan Qin; Fengling Yang; Ang Li; Edi Prifti; Yanfei Chen; Li Shao; Jing Guo; Emmanuelle Le Chatelier; Jian Yao; Lingjiao Wu; Jiawei Zhou; Shujun Ni; Lin Liu; Nicolas Pons; Jean Michel Batto; Sean P Kennedy; Pierre Leonard; Chunhui Yuan; Wenchao Ding; Yuanting Chen; Xinjun Hu; Beiwen Zheng; Guirong Qian; Wei Xu; S Dusko Ehrlich; Shusen Zheng; Lanjuan Li
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962

5.  Altered profile of human gut microbiome is associated with cirrhosis and its complications.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Phillip B Hylemon; Arun J Sanyal; Melanie B White; Pamela Monteith; Nicole A Noble; Ariel B Unser; Kalyani Daita; Andmorgan R Fisher; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  J Hepatol       Date:  2013-12-25       Impact factor: 25.083

6.  Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples.

Authors:  Nicola Segata; Susan Kinder Haake; Peter Mannon; Katherine P Lemon; Levi Waldron; Dirk Gevers; Curtis Huttenhower; Jacques Izard
Journal:  Genome Biol       Date:  2012-06-14       Impact factor: 13.583

7.  Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis.

Authors:  Angela Horvath; Florian Rainer; Mina Bashir; Bettina Leber; Bianca Schmerboeck; Ingeborg Klymiuk; Andrea Groselj-Strele; Marija Durdevic; Daniel E Freedberg; Julian A Abrams; Peter Fickert; Philipp Stiegler; Vanessa Stadlbauer
Journal:  Sci Rep       Date:  2019-08-19       Impact factor: 4.379

Review 8.  The salivary microbiota in health and disease.

Authors:  Daniel Belstrøm
Journal:  J Oral Microbiol       Date:  2020-02-04       Impact factor: 5.474

9.  Microbiome meta-analysis and cross-disease comparison enabled by the SIAMCAT machine learning toolbox.

Authors:  Jakob Wirbel; Konrad Zych; Morgan Essex; Nicolai Karcher; Ece Kartal; Guillem Salazar; Peer Bork; Shinichi Sunagawa; Georg Zeller
Journal:  Genome Biol       Date:  2021-03-30       Impact factor: 13.583

Review 10.  The Use of Rifaximin in Patients With Cirrhosis.

Authors:  Paolo Caraceni; Victor Vargas; Elsa Solà; Carlo Alessandria; Koos de Wit; Jonel Trebicka; Paolo Angeli; Rajeshwar P Mookerjee; François Durand; Elisa Pose; Aleksander Krag; Jasmohan S Bajaj; Ulrich Beuers; Pere Ginès
Journal:  Hepatology       Date:  2021-06-07       Impact factor: 17.425

View more
  2 in total

1.  Improving the Diagnostic Potential of Extracellular miRNAs Coupled to Multiomics Data by Exploiting the Power of Artificial Intelligence.

Authors:  Alessandro Paolini; Antonella Baldassarre; Stefania Paola Bruno; Cristina Felli; Chantal Muzi; Sara Ahmadi Badi; Seyed Davar Siadat; Meysam Sarshar; Andrea Masotti
Journal:  Front Microbiol       Date:  2022-06-09       Impact factor: 6.064

Review 2.  The Link between Gut Microbiota and Hepatic Encephalopathy.

Authors:  Sung-Min Won; Ki Kwang Oh; Haripriya Gupta; Raja Ganesan; Satya Priya Sharma; Jin-Ju Jeong; Sang Jun Yoon; Min Kyo Jeong; Byeong Hyun Min; Ji Ye Hyun; Hee Jin Park; Jung A Eom; Su Been Lee; Min Gi Cha; Goo Hyun Kwon; Mi Ran Choi; Dong Joon Kim; Ki Tae Suk
Journal:  Int J Mol Sci       Date:  2022-08-12       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.